{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:54:30Z","timestamp":1740182070375,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-024-00805-1","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T10:02:32Z","timestamp":1726048952000},"page":"1452-1454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody avidity meets multiple myeloma"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7409-3766","authenticated-orcid":false,"given":"Sigrid R.","family":"Ruuls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4365-3859","authenticated-orcid":false,"given":"Paul W. H. I.","family":"Parren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"204062071985417","DOI":"10.1177\/2040620719854171","volume":"10","author":"D Swan","year":"2019","unstructured":"Swan, D., Lynch, K., Gurney, M. & O'Dwyer, M. Ther. Adv. Hematol. 10, 2040620719854171 (2019).","journal-title":"Ther. Adv. Hematol."},{"key":"805_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu, Q., Yang, D., Li, H., Niu, T. & Tong, A. Mol. Biomed. 5, 25 (2024).","journal-title":"Mol. Biomed."},{"key":"805_CR3","doi-asserted-by":"publisher","first-page":"1394048","DOI":"10.3389\/fonc.2024.1394048","volume":"14","author":"RD Parrondo","year":"2024","unstructured":"Parrondo, R. D., Ailawadhi, S. & Cerchione, C. Front. Oncol. 14, 1394048 (2024).","journal-title":"Front. Oncol."},{"key":"805_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00821-1","author":"L Carretero-Iglesia","year":"2024","unstructured":"Carretero-Iglesia, L. et al. Nat. Cancer https:\/\/doi.org\/10.1038\/s43018-024-00821-1 (2024).","journal-title":"Nat. Cancer"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"NWCJ Van De Donk","year":"2018","unstructured":"Van De Donk, N. W. C. J., Richardson, P. G. & Malavasi, F. Blood 131, 13\u201329 (2018).","journal-title":"Blood"},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1182\/blood.V126.23.1798.1798","volume":"126","author":"GL Moore","year":"2015","unstructured":"Moore, G. L. et al. Blood 126, 1798\u20131798 (2015).","journal-title":"Blood"},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"e133757","DOI":"10.1172\/jci.insight.133757","volume":"5","author":"K Staflin","year":"2020","unstructured":"Staflin, K. et al. JCI Insight 5, e133757 (2020).","journal-title":"JCI Insight"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","volume":"21","author":"SC Oostindie","year":"2022","unstructured":"Oostindie, S. C., Lazar, G. A., Schuurman, J. & Parren, P. W. H. I. Nat. Rev. Drug Discov. 21, 715 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"805_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Nat. Rev. Drug Discov. 18, 585\u2013608 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"805_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yrtph.2017.09.001","volume":"90","author":"H Saber","year":"2017","unstructured":"Saber, H., Del Valle, P., Ricks, T. K. & Leighton, J. K. Regul. Toxicol. Pharmacol. 90, 144\u2013152 (2017).","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00805-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00805-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T10:03:35Z","timestamp":1729764215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00805-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00805-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"type":"electronic","value":"2662-1347"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"11 September 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.R.R. is an employee of Gyes (a biotechnology company developing therapeutic antibodies based on avidity-engineered molecules), and is a former employee of Genmab and Lava Therapeutics and owns stock of Genmab and Lava Therapeutics. P.W.H.I.P. is an employee of Gyes and the Leiden University Medical Center and a former employee of Genmab and Lava Therapeutics, owns options and\/or stock of Lava Therapeutics and Gyes, and is an inventor on patent applications relating to bispecific and avidity-engineered molecules, including T cell engagers.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}